IBEX Limited: A Hidden Growth Engine In Healthtech

Q2 2026 revenue rose 16.7% YoY to $164.2M, with adjusted EBITDA margin improving to 12.6% on cost efficiencies and favorable segment mix. The HealthTech segment grew 35% YoY and now represents 17.4% of revenue, and management is targeting $100M in HealthTech revenue by year-end, signaling a strategic pivot from traditional BPO toward higher-margin HealthTech leveraging AI and offshore labor. The combination of faster HealthTech growth and margin expansion supports a constructive outlook for profitability and medium-term growth.

Analysis

IBEX’s strategic move toward AI-enabled HealthTech changes the unit economics more than the headline top-line. Higher-margin software and services tend to convert cash faster and produce stickier revenue, but only after productization and recurring-contract scale; expect the true leverage to show up in gross margin and net retention metrics rather than one quarter’s adjusted EBITDA. Re-rating will require visible improvements in ARR-like metrics and multi-year client commitments, not just lump-sum project wins.

Competitively, incumbents that remain pure low-cost BPO are the most exposed — IBEX can extract pricing power from clients if it delivers measurable clinical or cost-out outcomes tied to payer/provider KPIs. A second-order supply effect: demand for labeled clinical data, annotation labor, and regulatory-compliance tooling will surge, lifting wages and input costs in offshore hubs and advantaging operators with scale and existing Compliance/Privacy infrastructure. This pivot also increases IBEX’s attractiveness as an M&A target for strategic health-tech consolidators and digital-health PE funds, creating a plausible takeover premium path.

Key risks are operational and regulatory rather than purely macro. Primary reversal scenarios are (1) slower-than-expected enterprise sales cycles causing higher upfront investment with delayed margin payoff, (2) adverse regulatory or data-privacy events that force remediation costs, and (3) a bump in offshore labor inflation that erodes the claimed cost advantage. Watchables on a 0–3 month horizon are contract wins and client mix disclosure, on 3–12 months margin and ARR-style metrics, and on 12–36 months potential strategic exits or M&A interest that could crystallize valuation upside.

Key Decisions for Investors

• Long IBEX equity (6–12 month horizon): initial size 2–3% NAV. Add to position on two confirmations — 1) sequential increase in recurring-similar revenue share; 2) one large multi-year contract announcement. Target 30–40% upside; hard stop at 18–20% downside to limit execution/operational risk.
• Pair trade (6–12 months): Long IBEX / Short TTEC (equal notional). Rationale: capture relative re-rating as IBEX executes HealthTech mix shift while TTEC remains exposed to legacy CX/BPO. Target spread compression equivalent to ~25% relative outperformance; keep pair hedged to sector moves and cap position to 1.5% NAV each leg.
• Option/hedge (3–9 months): If liquid, buy IBEX 12-month call spread (moderate debit) or alternatively buy stock and purchase 6-month puts (protective hedge). Use options to express asymmetric upside to a successful productization narrative while capping downside — aim for >2.5:1 reward-to-cost on the spread structure.
• Event trigger discipline: increase exposure by +1–2% NAV on any quarter that shows sequential improvement in gross margin tied to HealthTech mix, or trim to <0.5% if management withdraws medium-term guidance or discloses material client concentration loss. Monitor regulatory headlines closely and set alerts for HIPAA/privacy incidents or offshore labor disputes.